ES2052228T3 - Granulados doblemente recubiertos. - Google Patents

Granulados doblemente recubiertos.

Info

Publication number
ES2052228T3
ES2052228T3 ES90810661T ES90810661T ES2052228T3 ES 2052228 T3 ES2052228 T3 ES 2052228T3 ES 90810661 T ES90810661 T ES 90810661T ES 90810661 T ES90810661 T ES 90810661T ES 2052228 T3 ES2052228 T3 ES 2052228T3
Authority
ES
Spain
Prior art keywords
double coated
coated granulates
capsules
granules
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90810661T
Other languages
English (en)
Inventor
Dagmar Dr Wirth
Christian Bucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2052228T3 publication Critical patent/ES2052228T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

EL INVENTO SE REFIERE A CAPSULAS QUE ESTAN FORMADAS BASICAMENTE POR PAMIDRONATOS DISODICOS; SE APLICAN POR VIA ORAL Y SE LLENAN CON GRANULOS DE DOBLE RECUBRIMIENTO Y SE CARACTERIZAN PORQUE EL RECUBRIMIENTO INTERIOR ES HIDROFILO Y ELASTICO Y EL RECUBRIMIENTO EXTERIOR ES RESISTENTE A LA ACCION DEL JUGO GASTRICO Y SOLUBLE AL JUGO INTESTINAL.
ES90810661T 1989-09-07 1990-08-30 Granulados doblemente recubiertos. Expired - Lifetime ES2052228T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH324589 1989-09-07

Publications (1)

Publication Number Publication Date
ES2052228T3 true ES2052228T3 (es) 1994-07-01

Family

ID=4251793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90810661T Expired - Lifetime ES2052228T3 (es) 1989-09-07 1990-08-30 Granulados doblemente recubiertos.

Country Status (21)

Country Link
US (1) US5096717A (es)
EP (1) EP0421921B1 (es)
JP (1) JP3009713B2 (es)
KR (1) KR910005852A (es)
AT (1) ATE104856T1 (es)
AU (1) AU623036B2 (es)
CA (1) CA2024631C (es)
DD (1) DD298049A5 (es)
DE (1) DE59005517D1 (es)
DK (1) DK0421921T3 (es)
ES (1) ES2052228T3 (es)
FI (1) FI93169C (es)
HU (1) HU207447B (es)
IE (1) IE63668B1 (es)
IL (1) IL95558A (es)
MX (1) MX22254A (es)
NO (1) NO176646C (es)
NZ (1) NZ235187A (es)
PH (1) PH27186A (es)
PT (1) PT95209B (es)
ZA (1) ZA907100B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
HUT67007A (en) * 1991-07-24 1995-01-30 Enzacor Pty Ltd Preparations containing biologically activ agent wich are absorbed in the superior intestinal tract of animals
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2687291B1 (fr) * 1992-02-17 1994-06-03 Sfbd Vivis Aliment pour sportif et son procede de fabrication.
TW237386B (es) * 1992-04-15 1995-01-01 Ciba Geigy
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
DE4236090C1 (de) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmazeutische Zubereitung für die Fluoridionen-Versorgung
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
TR200000111T2 (tr) * 1997-06-11 2000-05-22 The Procter & Gamble Company Gelişmiş üst gastrointestinal traktus güvenliği için film kaplı tablet.
CA2270975C (en) 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
AU2127200A (en) * 1999-11-02 2001-05-14 Cipla Limited A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
NZ527832A (en) * 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
EP1781258A1 (en) * 2004-08-20 2007-05-09 Mepha AG Formulations of bisphosphonates
AU2006253007B2 (en) * 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
ATE512211T1 (de) * 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
IE903239A1 (en) 1991-03-13
NO903892L (no) 1991-03-08
FI93169B (fi) 1994-11-30
FI93169C (fi) 1995-03-10
NO176646B (no) 1995-01-30
EP0421921A1 (de) 1991-04-10
PH27186A (en) 1993-04-16
NO903892D0 (no) 1990-09-06
EP0421921B1 (de) 1994-04-27
JPH0399016A (ja) 1991-04-24
MX22254A (es) 1993-12-01
CA2024631A1 (en) 1991-03-08
IE63668B1 (en) 1995-05-31
PT95209A (pt) 1991-05-22
ATE104856T1 (de) 1994-05-15
JP3009713B2 (ja) 2000-02-14
AU6228390A (en) 1991-03-14
FI904341A0 (fi) 1990-09-03
ZA907100B (en) 1991-05-29
AU623036B2 (en) 1992-04-30
US5096717A (en) 1992-03-17
NO176646C (no) 1995-05-10
HU207447B (en) 1993-04-28
HU905812D0 (en) 1991-03-28
DD298049A5 (de) 1992-02-06
IL95558A0 (en) 1991-06-30
CA2024631C (en) 2000-11-21
NZ235187A (en) 1992-03-26
HUT59008A (en) 1992-04-28
PT95209B (pt) 1998-06-30
KR910005852A (ko) 1991-04-27
DK0421921T3 (da) 1994-05-30
DE59005517D1 (de) 1994-06-01
IL95558A (en) 1995-08-31

Similar Documents

Publication Publication Date Title
ES2052228T3 (es) Granulados doblemente recubiertos.
NO871790D0 (no) Fremgangsmaate for fremstilling av et oralt farmasoeytisk preparat.
NO910828L (no) Preparat for behandling av erektil funksjonssvikt.
NO863670L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat av et hydrofobt legemiddel.
NO166639C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte, basiske 2-aminotetraliner.
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
NO913008L (no) Fremgangsmaate for fremstilling av fenylacetamid-derivater.
NO169473C (no) Fremgangsmaate for fremstilling av sfaeriske partikler.
NO831610L (no) Fremgangsmaate for fremstilling av terapeutisk aktive oxicamderivater.
NO863671D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-2-heterocykloalkylpyrido(4,3)indoler.
NO881643L (no) Fremgangsmaate for fremstilling av hoeystabile mykgelatinkapsler for terapeutiske formaal.
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO891574L (no) Fremgangsmaate for fremstilling av farmasoeytisk anvendbareforbindelser.
NO880325L (no) Fremgangsmaate for fremstilling av n,n-(dibenzoheksatrienylen)ureaer.
NO901893L (no) Fremgangsmaate for fremstilling av penemforbindelser.
NO168247C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-metoksy-alkyl-ammonium-tetrahydrofuraner.
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
FI890065A0 (fi) Foerfarande foer framstaellning av 5,8,13, 14-tetrahydrobenz/5,6/isoindolo/2,1-b/isokinolin-8,13-dionderivat.
NO891677L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenetanolamin-derivater.
NO890506D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kloranilin-derivater.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 421921

Country of ref document: ES